PharmAsia News

Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb

Ranbaxy has acquired the U.S. rights to a group of 13 branded dermatology products from Bristol-Myers Squibb, the Indian firm announced May 28. Bristol retains ex-U.S. rights to the products.

Weekly Roundup: May 29, 2007

• China Sentences Former Food and Drugs Chief to Death (China)
• Japan Tobacco Cuts Its Pharmaceutical-related R&D Spending (Japan)
• Rude Awakening Could Await China (China)
• The Life Sciences Industry in China (China)
• Japan's Pharm Industry Poised to Experience Rapid Change (Japan)
• Western Drug Makers Expand Use of India's Scientific Talent (India)
• Avandia Concerns Reopen a Wider Debate (Japan)
• Singapore Among Top 3 Destinations in Asia for Pharmaceutical Investments (Singapore)
• Pharmaniaga Mulls Changes in Business Strategy in China (Malaysia)
• GlaxoSmithKline Says Cervarix Is Approved in Australia (Australia)
• Drug Lobby Driving PBS Changes, Says Expert (Australia)
• WHO Halts Use of Euvax B Vaccine for Hepatitis B (Vietnam)
• Int'l Pharmaceutical Exhibition Opens in Vietnam (Vietnam)
• Due to China's Protest, North Korea's Drug Production Facility Partly Closed (North Korea)

GSK Jumps Into Growing China R&D Space

GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24.

Asia Set To Become New Center Of Pharma: PricewaterhouseCoopers Report

Asia is poised to become the new center of the global pharmaceutical industry, according to a PricewaterhouseCoopers report, with China and India set to be the largest beneficiaries.

Sun Pharmaceutical Moves To Buy Taro In $450 Million Deal

Sun Pharmaceutical has signed a definitive agreement to acquire Haifa, Israel-based Taro Pharmaceutical Industries in a deal valued at more than $450 million, the companies announced May 21.

Weekly Roundup: May 21, 2007

• Big Pharma to Expand in Asia (Asia)
• Multinational Drug Makers File Suit With Korean Firms (South Korea)
• Big Drug Makers in Japan Report Mixed Results (Japan)
• Government Eyes Greater Use of Generic Drugs (Japan)
• Shanghai Pharma to Set Up JV with Japanese Distributor (China)
• Dr Reddy's to Set up Two SEZs (India)
• Overseas Funds Flood China Pharma Sector (China)
• India Lags Behind in Biotech, Says Ernst Report (India)
• India's Sun Pharmaceutical Buys Taro (India)
• Website Sued for Biostime Article (China)
• Cuba, China Sign Agreement for Biotech Joint Venture (China)
• Letters: Misuse of Pharmaceutical Drugs (Pakistan)
• No Funding for Cervical Vaccine (New Zealand)
• China's Pharmaceutical Profit Growth Lags Behind Other Industries (China)

China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics - Sidley Austin

China's State Food and Drug Administration would require clinical studies for follow-on biologics under draft drug registration regulations published in March, according to comments submitted to SFDA by the Beijing office of U.S.-based law firm Sidley Austin.

Delays From Import Alert Highlight Communication, Analytical Testing Issues

Firms have yet to prove any of the nearly 50 shipments of vegetable protein concentrates imported from China since April 27 are free of melamine, Dr. David Acheson, FDA's assistant commissioner for food protection, said May 17.

CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY.

FDA Discusses Industry's Food Safety Burden, Plans To Knock On Doors

Food importers and manufacturers hold the key to ensuring the safety of the U.S. food supply and that responsibility is only increasing, FDA stresses as the investigation into contaminated vegetable protein continues.